DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT02280629
- Locations
- 🇩🇪
Agaplesion Markus-Krankenhaus, Frankfurt a.M., Germany
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 468
- Registration Number
- NCT02142725
- Locations
- 🇩🇪
Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine, Frankfurt a.M., Germany
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 44
- Registration Number
- NCT02142634
- Locations
- 🇩🇪
Centre for Digestive Diseases, Hamburg, Germany
🇸🇪University Hospital of Linköping, Dept. of Gastroenterology and Hepatology, Linköping, Sweden
Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 320
- Registration Number
- NCT01966783
- Locations
- 🇩🇪
Charité-Campus Benjamin Franklin Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Evang. Krankenhaus Kalk, Medical Department, Cologne, Germany
Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis
- Conditions
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 204
- Registration Number
- NCT01847664
- Locations
- 🇩🇪
Evangelisches Krankenhaus Kalk, Cologne, Nordrhein-Westfalen, Germany
Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 159
- Registration Number
- NCT01755507
- Locations
- 🇦🇹
Prof. M. Trauner, Wien, Austria
🇩🇪Prof. Michael Manns, Hannover, Germany
🇳🇴Kirsten Boberg, Oslo, Norway
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 306
- Registration Number
- NCT01745770
- Locations
- 🇩🇪
Med. Klinik 1 - Markus-Krankenhaus, Frankfurt, Hessen, Germany
Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 123
- Registration Number
- NCT01627262
- Locations
- 🇩🇪
Ev. Krankenhaus Kalk, University of Cologne, Köln, Germany
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 65
- Registration Number
- NCT01510860
- Locations
- 🇩🇪
Klinikum Grosshadern, Munich, Germany
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 254
- Registration Number
- NCT01279577
- Locations
- 🇩🇪
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt a.M., Hessen, Germany